Swiss National Bank Decreases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Swiss National Bank cut its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 7.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 152,800 shares of the company’s stock after selling 12,400 shares during the period. Swiss National Bank owned approximately 0.17% of Intellia Therapeutics worth $5,695,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. State of Wisconsin Investment Board grew its holdings in Intellia Therapeutics by 0.4% during the fourth quarter. State of Wisconsin Investment Board now owns 68,629 shares of the company’s stock worth $2,394,000 after acquiring an additional 297 shares during the period. Franklin Resources Inc. boosted its stake in shares of Intellia Therapeutics by 2.8% during the 4th quarter. Franklin Resources Inc. now owns 10,790 shares of the company’s stock worth $376,000 after acquiring an additional 298 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Intellia Therapeutics by 20.2% during the 1st quarter. Daiwa Securities Group Inc. now owns 2,199 shares of the company’s stock worth $82,000 after acquiring an additional 370 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Intellia Therapeutics by 7.8% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,553 shares of the company’s stock worth $207,000 after acquiring an additional 401 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in shares of Intellia Therapeutics by 149.1% during the 1st quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $30,000 after acquiring an additional 474 shares in the last quarter. 87.72% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Eliana Clark sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the sale, the executive vice president now owns 45,146 shares in the company, valued at $2,031,570. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Intellia Therapeutics news, EVP Eliana Clark sold 5,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the completion of the transaction, the executive vice president now owns 45,146 shares in the company, valued at approximately $2,031,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Muna Bhanji sold 1,867 shares of the stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $39.30, for a total transaction of $73,373.10. Following the completion of the transaction, the director now owns 12,526 shares of the company’s stock, valued at approximately $492,271.80. The disclosure for this sale can be found here. Insiders have sold a total of 7,492 shares of company stock valued at $324,174 in the last quarter. Company insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NTLA shares. Barclays lowered their target price on shares of Intellia Therapeutics from $148.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, August 4th. Citigroup decreased their price target on shares of Intellia Therapeutics from $44.00 to $40.00 and set a “neutral” rating for the company in a research report on Friday, August 4th. BMO Capital Markets upped their price objective on Intellia Therapeutics from $57.00 to $64.00 in a research report on Friday, May 5th. Canaccord Genuity Group reduced their price objective on shares of Intellia Therapeutics from $66.00 to $65.00 and set a “buy” rating for the company in a research report on Monday, August 7th. Finally, StockNews.com started coverage on shares of Intellia Therapeutics in a report on Thursday, May 18th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $81.89.

Intellia Therapeutics Stock Up 0.5 %

Intellia Therapeutics stock opened at $38.19 on Wednesday. The firm has a fifty day moving average of $40.79 and a 200-day moving average of $40.25. Intellia Therapeutics, Inc. has a 52-week low of $32.44 and a 52-week high of $69.28. The firm has a market capitalization of $3.38 billion, a P/E ratio of -6.99 and a beta of 1.84.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 3rd. The company reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.08). Intellia Therapeutics had a negative net margin of 854.92% and a negative return on equity of 41.64%. The business had revenue of $13.59 million for the quarter, compared to the consensus estimate of $12.08 million. During the same quarter in the previous year, the firm earned ($1.33) EPS. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, research analysts expect that Intellia Therapeutics, Inc. will post -5.59 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.